Compared with HER2-negative tumors, HER2-positive tumors were not different concerning race/ethnicity, tumor histology, tumor size, regional node involvement, and PMRT, but HER2-positive patients received more PMCT (P < 0.001). The gene discussed is ERBB2; the disease is neoplasm.